Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy flexes muscle.

Thierry VandenDriessche1

  • 1Center for Transgene Technology & Gene Therapy, University of Leuven-Faculty of Medicine, Flanders Interuniversity Institute for Biotechnology (VIB), Herestraat 49 B-3000 Leuven, Belgium. thierry.vandendriessche@med.kuleuven.be

The Journal of Gene Medicine
|July 2, 2005
PubMed
Summary

Gene therapy shows promise for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, offering new hope where treatments are lacking. These advances in gene therapy technology are crucial for patients and families affected by these progressive muscle-degenerating diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased Gene Therapy Efficacy Through the Use of Extended Half-Life Clotting Factors.

Blood advances·2026
Same author

Matchmaking gene therapy with mimetic antibodies.

Blood·2025
Same author

CRISPR and gene editing technologies for bleeding disorders.

Therapeutic advances in hematology·2025
Same author

Long-Term Functional Correction of Pompe Disease and Increased α-Glucosidase Expression after Gene Therapy with Novel Combinations of Muscle-Targeted Transcriptional <i>Cis</i>-Regulatory Elements.

Human gene therapy·2025
Same author

Comprehensive analysis of off-target and on-target effects resulting from liver-directed CRISPR-Cas9-mediated gene targeting with AAV vectors.

Molecular therapy. Methods & clinical development·2024
Same author

Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy.

Molecular metabolism·2024

Area of Science:

  • Neurology
  • Genetics
  • Biotechnology

Background:

  • Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) are progressive muscle-degenerating diseases with limited treatment options.
  • DMD results from dystrophin gene mutations, while ALS causes motoneuron degeneration, with familial cases linked to SODG93A mutations.
  • Both conditions often lead to fatal cardiac or pulmonary dysfunction due to muscle deterioration.

Discussion:

  • Gene therapy has demonstrated significant potential in preclinical animal models for both DMD and ALS.
  • Effective gene therapy for DMD involves gene augmentation, whereas ALS may require gene expression inhibition due to dominant gain-of-function mutations.
  • Challenges remain in achieving widespread gene transfer, particularly for ALS treatment.

Key Insights:

Related Experiment Videos

  • Recent studies in animal models highlight gene therapy's efficacy for DMD and ALS.
  • Gene therapy represents a significant advancement over current treatment limitations for these devastating diseases.
  • Understanding the genetic basis is crucial for developing targeted gene therapy strategies.

Outlook:

  • Gene therapy offers the most promising therapeutic avenue for patients with DMD and ALS.
  • Further research is needed to overcome gene transfer challenges and refine therapeutic approaches.
  • Continued development in gene therapy technology could revolutionize the management of neuromuscular disorders.